Technical Analysis for EVG - Evgen Pharma Plc

Grade Last Price % Change Price Change
grade B 20.0 3.90% 0.75
EVG closed up 3.9 percent on Friday, May 17, 2019, on 2.07 times normal volume.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical EVG trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.90%
Calm After Storm Range Contraction 3.90%
Narrow Range Bar Range Contraction 3.90%
Wide Bands Range Expansion 3.90%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.90%
Calm After Storm Range Contraction 3.90%
Narrow Range Bar Range Contraction 3.90%
Wide Bands Range Expansion 3.90%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.90%
Calm After Storm Range Contraction 3.90%

Older signals for EVG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Chemistry Medicine Cancer Rtt Drug Development Pharmaceutical Products Breast Cancer Intensive Care Medicine Multiple Sclerosis Neurosurgery Organic Chemistry Prostate Cancer Stem Cells
Is EVG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 15 [$$] Drug start-ups move out of UK’s ‘golden triangle’
See more EVG news...
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 13.1
Average Volume 681,216
200-Day Moving Average 17.2522
50-Day Moving Average 19.0208
20-Day Moving Average 20.825
10-Day Moving Average 19.875
Average True Range 1.3954
ADX 26.52
+DI 25.5028
-DI 33.3618
Chandelier Exit (Long, 3 ATRs ) 19.5638
Chandelier Exit (Short, 3 ATRs ) 19.1862
Upper Bollinger Band 23.9157
Lower Bollinger Band 17.7343
Percent B (%b) 0.37
BandWidth 29.682593
MACD Line 0.0801
MACD Signal Line 0.3999
MACD Histogram -0.3198
Fundamentals Value
Market Cap 14.57 Million
Num Shares 729 Thousand
EPS -62.34
Price-to-Earnings (P/E) Ratio -0.32
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.28
Resistance 3 (R3) 21.13 20.57 21.06
Resistance 2 (R2) 20.57 20.24 20.64 20.99
Resistance 1 (R1) 20.28 20.04 20.43 20.43 20.92
Pivot Point 19.72 19.72 19.79 19.79 19.72
Support 1 (S1) 19.43 19.39 19.58 19.58 19.08
Support 2 (S2) 18.87 19.19 18.94 19.01
Support 3 (S3) 18.58 18.87 18.94
Support 4 (S4) 18.73